Εμφανίζονται 1 - 20 Αποτελέσματα από 68 για την αναζήτηση '"ДИАБЕТИЧЕСКАЯ ПОЛИНЕВРОПАТИЯ"', χρόνος αναζήτησης: 0,80δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Συνεισφορές: The investigation has not been sponsored, Исследование не имело спонсорской поддержки

    Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 4 (2024); 21-27 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 4 (2024); 21-27 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/2328/1698; Williams R, Karuranga S, Malanda B, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9 th edition. Diabetes Res Clin Pract. 2020 Apr;162:108072. doi:10.1016/j.diabres.2020.108072. Epub 2020 Feb 13.; Дедов ИИ, Концевая АВ, Шестакова МВ и др. Экономические затраты на сахарный диабет 2 типа и его основные сердечно-сосудистые осложнения в Российской Федерации. Сахарный диабет. 2016;19(6):518-27. doi:10.14341/DM8153.; Khan KS, Andersen H. The Impact of Diabetic Neuropathy on Activities of Daily Living, Postural Balance and Risk of Falls – A Systematic Review. J Diabetes Sci Technol. 2022 Mar;16(2):289-94. doi:10.1177/1932296821997921. Epub 2021 Mar 14.; Ахмеджанова ЛТ, Мандра ЕВ. Болевая диабетическая полиневропатия: современные подходы к диагностике и лечению. Медицинский Совет. 2022;(23):86-92. doi:10.21518/2079-701X-2022-16-23-86-92; Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019 Dec;7(12):938-48. doi:10.1016/S2213-8587(19)30081-6. Epub 2019 Oct 14.; Abdissa D. Prevalence and associated factors of painful diabetic peripheral neuropathy among diabetic patients on follow up at Jimma University Medical Center. J Diabetes Metab Disord. 2020 Oct 15;19(2):1407-13. doi:10.1007/s40200-020-00661-7; Selvarajah D, Cash T, Sankar A, et al. The contributors of emotional distress in painful diabetic neuropathy. Diab Vasc Dis Res. 2014 Jul;11(4):218-25. doi:10.1177/1479164114522135. Epub 2014 May 12.; Zafeiri M, Tsioutis C, Kleinaki Z, et al. Clinical Characteristics of Patients with co-Existent Diabetic Peripheral Neuropathy and Depression : A Systematic Review. Exp Clin Endocrinol Diabetes. 2021 Feb;129(2):77-85. doi:10.1055/a-0741-6937. Epub 2018 Sep 26.; American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S231-S243. doi:10.2337/dc24-S012; Elafros MA, Andersen H, Bennett DL, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022 Oct;21(10):922-36. doi:10.1016/S1474-4422(22)00188-0; Racaru S, Sturt J, Celik A. The Effects of Psychological Interventions on Diabetic Peripheral Neuropathy : A Systematic Review and Meta-Analysis. Pain Manag Nurs. 2021 Jun;22(3):302-11. doi:10.1016/j.pmn.2020.11.001. Epub 2020 Dec 13.; Moisset X, Bouhassira D, Avez Couturier J, et al. Pharmacological and non-pharmacological treatments for neuropathic pain : Systematic review and French recommendations. Rev Neurol (Paris). 2020 May;176(5):325-52. doi:10.1016/j.neurol.2020.01.361. Epub 2020 Apr 7.; Manojlovic D, Kopse EI. The effectiveness of aerobic exercise for pain management in patients with fibromyalgia. Eur J Transl Myol. 2023 Jul 14;33(3):11423. doi:10.4081/ejtm.2023.11423; Парфенов ВА, Ламкова ИА. Эффективность кинезитерапии при хронической неспецифической люмбалгии. Анналы клинической и экспериментальной неврологии. 2021;15(3):35-42. doi:10.54101/ACEN.2021.3.4; Holmes CJ, Hastings MK. The Application of Exercise Training for Diabetic Peripheral Neuropathy. J Clin Med. 2021 Oct 28;10(21):5042. doi:10.3390/jcm10215042; Dyck PJ, Albers JW, Andersen H, et al; Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011 Oct;27(7):620-8. doi:10.1002/dmrr.1226; Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi:10.1002/acr.20543; Bastyr EJ 3rd, Price KL, Bril V; MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005 Aug;27(8):1278-94. doi:10.1016/j.clinthera.2005.08.002; Beck AT, Steer RA, Brown G. Beck Depression Inventory–II [Database record]. APA. PsycTests. 1996. doi:10.1037/t00742-000; Spielberger CD. Test Anxiety Inventory: Preliminary professional manual. Menlo Park; 1980.; Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi:10.1249/01.MSS.0000078924.61453.FB; Shi Y, Wu W. Multimodal non-invasive non-pharmacological therapies for chronic pain: mechanisms and progress. BMC Med. 2023 Sep 29;21(1):372. doi:10.1186/s12916-023-03076-2; Sletten CD, Kurklinsky S, Chinburapa V, Ghazi S. Economic analysis of a comprehensive pain rehabilitation program: a collaboration between Florida Blue and Mayo Clinic Florida. Pain Med. 2015 May;16(5):898-904. doi:10.1111/pme.12679. Epub 2015 Feb 3.; Wilhelm JC, Xu M, Cucoranu D, et al. Cooperative roles of BDNF expression in neurons and Schwann cells are modulated by exercise to facilitate nerve regeneration. J Neurosci. 2012 Apr 4;32(14):5002-9. doi:10.1523/JNEUROSCI.1411-11.2012; Zaccaria S, Di Perna P, Giurato L, et al. Diabetic Polyneuropathy and Physical Activity in Type 1 Diabetes Mellitus: A Cross-Sectional Study. J Clin Med. 2023 Oct 18;12(20):6597. doi:10.3390/jcm12206597; Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006 Jun;29(6):1294-9. doi:10.2337/dc06-0224; Tatikola SP, Natarajan V, Desai VK, et al. Effect of various exercise protocols on neuropathic pain in individuals with type 2 diabetes with peripheral neuropathy : A systematic review and meta-analysis. Diabetes Metab Syndr. 2022 Sep;16(9):102603. doi:10.1016/j.dsx.2022.102603. Epub 2022 Aug 27.; Zhang YH, Hu HY, Xiong YC, et al. Exercise for Neuropathic Pain : A Systematic Review and Expert Consensus. Front Med (Lausanne). 2021 Nov 24;8:756940. doi:10.3389/fmed.2021.756940; Luo J, Zhu HQ, Gou B, Zheng YL. Mechanisms of exercise for diabetic neuropathic pain. Front Aging Neurosci. 2022 Oct 12;14:975453. doi:10.3389/fnagi.2022.975453; Leitzelar BN, Koltyn KF. Exercise and Neuropathic Pain : A General Overview of Preclinical and Clinical Research. Sports Med Open. 2021 Mar 22;7(1):21. doi:10.1186/s40798-021-00307-9; Kluding PM, Pasnoor M, Singh R, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012 Sep-Oct;26(5):424-9. doi:10.1016/j.jdiacomp.2012.05.007. Epub 2012 Jun 18.; Hamed N, Raoof N. Effect of high intensity interval training on diabetic obese women with polyneuropathy: A randomized controlled clinical trial. Phys Ther Rehabil. 2014;1(4):1-8. doi:10.7243/2055-2386-1-4; Nadi M, Marandi SM, Esfarjani F, et al. The Comparison between Effects of 12 weeks Combined Training and Vitamin D Supplement on Improvement of Sensory-motor Neuropathy in type 2 Diabetic Women. Adv Biomed Res. 2017 May 2;6:55. doi:10.4103/2277-9175.205528; Stubbs EB Jr, Fisher MA, Miller CM, et al. Randomized Controlled Trial of Physical Exercise in Diabetic Veterans With Length-Dependent Distal Symmetric Polyneuropathy. Front Neurosci. 2019 Feb 11;13:51. doi:10.3389/fnins.2019.00051; Cox ER, Gajanand T, Burton NW, et al. Effect of different exercise training intensities on musculoskeletal and neuropathic pain in inactive individuals with type 2 diabetes – Preliminary randomised controlled trial. Diabetes Res Clin Pract. 2020 Jun;164:108168. doi:10.1016/j.diabres.2020.108168. Epub 2020 Apr 29.; Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012 Oct;142 Suppl:S8-21. doi:10.1016/S0165-0327(12)70004-6; Tang NKY, Salkovskis PM, Hodges A, et al. Effects of mood on pain responses and pain tolerance: an experimental study in chronic back pain patients. Pain. 2008 Aug 31;138(2):392-401. doi:10.1016/j.pain.2008.01.018. Epub 2008 Mar 5.; Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology. 2022 Jan 4;98(1):31-43. doi:10.1212/WNL.0000000000013038; Головачева АА, Головачева ВА. Кинезиотерапия при хронической боли в спине и сочетанной головной боли напряжения. Российский неврологический журнал. 2023;28(3):61-8. doi:10.30629/2658-7947-2023-28-3-61-68; Головачева ВА, Табеева ГР, Фатеева ТГ. Ведение пациентов со скелетно-мышечной болью в спине и коморбидной тревогой. Медицинский Совет. 2022;(23):60-6. doi:10.21518/2079-701X-2022-16-23-60-66

  2. 2
    Academic Journal

    Συγγραφείς: Tkachuk, N. P., Gryb, V. A.

    Πηγή: Український неврологічний журнал; № 3—4 (2018); 46—51
    Ukrainian Neurological Journal; № 3—4 (2018); 46—51
    Украинский неврологический журнал; № 3—4 (2018); 46—51

    Περιγραφή αρχείου: application/pdf

    Σύνδεσμος πρόσβασης: http://ukrneuroj.com.ua/article/view/UNJ2018-3-46

  3. 3
    Academic Journal

    Συνεισφορές: This article has been supported by Kanonfarma prodakshn, Статья спонсируется компанией ЗАО «Канонфарма продакшн»

    Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 3 (2021); 99-106 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 3 (2021); 99-106 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-3

    Περιγραφή αρχείου: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/1584/1262; Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017 Jun 27;317(24):2515-23. doi:10.1001/jama.2017.7596; International Diabetes Federation Atlas. 8th ed. 2017. Available from: https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf; Котов СВ, Калинин АП, Рудакова ИГ. Диабетическая нейропатия. Москва: МИА; 2011. 438 с.; Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi:10.2337/dc10-1303; Babizhayev MA, Nosikov VV, Strokov IA, et al. The role of oxidative stress in diabetic neuropathy: generation of free radical species in the glycation reaction and gene polymorphisms encoding antioxidant enzymes to genetic susceptibility to diabetic neuropathy in population of type I diabetic patients. Cell Biochem Biophys. 2015 Apr;71(3):1425-43. doi:10.1007/s12013-014-0365-y; Strokov IA, Bursa TR, Drepa OI, et al. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol. 2003 Dec;40 Suppl 2:S375-9. doi:10.1007/s00592-003-0123-x; Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014 Aug;14(8):473. doi:10.1007/s11910-014-0473-5; Строков ИА, Мельниченко ГА, Альбекова ЖС и др. Распространенность и факторы риска развития диабетической полиневропатии у стационарных больных сахарным диабетом 1-го типа. Нервно-мышечные болезни. 2012;(1):25-31. doi:10.17650/2222-8721-2012-0-1-25-31; The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995 Apr 15;122(8):561-8. doi:10.7326/0003-4819-122-8-199504150-00001; Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012 Jun 13;6(6):CD007543. doi:10.1002/14651858.CD007543.pub2; Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25. doi:10.2337/diabetes.54.6.1615; Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008 Oct;120(1):1-34. doi:10.1016/j.pharmthera.2008.05.005. Epub 2008 Jun 13.; Зотова ЕВ, Савостьянов КВ, Чистяков ДА и др. Поиск ассоциации полиморфных маркеров генов, кодирующих ферменты антиоксидантной защиты с диабетической полинейропатией у больных сахарным диабетом типа 1. Молекулярная биология. 2004;(2):244-9.; Зотова ЕВ, Чистяков ДА, Савостьянов КВ и др. Изучение ассоциации полиморфных маркеров Ala(-9) Val гена SOD2 и Arg213Gly гена SOD3 с диабетической полинейропатией у больных сахарным диабетом типа 1. Молекулярная биология. 2003;(3):345-8.; Malic RA, Tesfaye S, Thompson SD, et al. Microangiopathy in human diabetic neuropathy: relationship between capilliary abnormalities and severity of neuropathy. Diabetologia. 1993 May;36(5):454-9. doi:10.1007/BF00402283; Giannini C, Dyck PJ. Ultrastructural morphometric features in human sural nerve microvessels. J Neuropathol Exp Neurol. 1993 Jul;52(4):361-9. doi:10.1097/00005072-199307000-00003; Caneron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets. 2008 Jan;9(1):60-7. doi:10.2174/138945008783431718; Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006 Jul;108(5):477-81. doi:10.1016/j.clineuro.2005.08.003. Epub 2005 Sep 16.; Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi:10.1016/S1474-4422(14)70251-0. Epub 2015 Jan 7.; Vincent AM, Callaghan BC, Smith AL, et al. Fiabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011 Sep 13;7(10):573-83. doi:10.1038/nrneurol.2011.137; Boulton AJ, Kempler P, Ametov A, et al. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev. 2013 Jul;29(5):327-33. doi:10.1002/dmrr.2397; Строков ИА, Манухина ЕБ, Бахтина ЛЮ и др. Состояние эндогенных протекторных систем у больных инсулинзависимым сахарным диабетом с полинейропатией: эффект антиоксидантной терапии. Бюллетень экспериментальной биологии и медицины. 2000;130(10):437-41.; Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radic Biol Med. 1999 Jun;26(11-12):1495-500. doi:10.1016/s0891-5849(99)00011-8; Haak ES, Usadel KH, Kohleisen M, et al. The effect of α-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res. 1999 Jul;58(1):28-34. doi:10.1006/mvre.1999.2151; Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 Dec;38(12):1425-33. doi:10.1007/BF00400603; Строков ИА, Козлова НА, Мозолевский ЮВ. Эффективность внутривенного введения трометамоловой соли тиоктовой (α-липоевой) кислоты при диабетической невропатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 1999;(6):18-22.; Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with antioxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2):114-21. doi:10.1111/j.1464-5491.2004.01109.x; Ruhnau KJ, Meissner HP, Finn JR, et al. Effect of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diab Med. 1999 Dec;16(12):1040-3. doi:10.1046/j.1464-5491.1999.00190.x; Ziegler D, Ametov A, Barinov A, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70. doi:10.2337/dc06-1216; Строков ИА, Фокина АС, Головачева ВА, Кочетов АГ. Эффективность тиолепты при диабетической полиневропатии (по данным исследования ЭТИКА). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(5):36-40.; Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetic Care. 2017 Jan;40(1):136-54. doi:10.2337/dc16-2042; Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi:10.2337/dc11-0503. Epub 2011 Jul 20.; Strokov IA, Novosadova MV, Lavrova IN, et al. The prolonged clinical effect of tioctic acid in symptomatic distal diabetic polyneuropathy. Abstr. of the 14th Annual Scientific Meeting of the DFSG and NEURODIAB, Regensburg, Germany, September 2–5 2004; 195 p.; Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with antioxidant thioctic acid (alpha-lipoic acid): a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Rad Res. 1999 Sep;31(3):171-9. doi:10.1080/10715769900300721

  4. 4
    Academic Journal

    Πηγή: Meditsinskiy sovet = Medical Council; № 19 (2021); 126-133 ; Медицинский Совет; № 19 (2021); 126-133 ; 2658-5790 ; 2079-701X

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/6541/5926; Alonso-Lana S., Marquié M., Ruiz A, Boada M. Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. Front Aging Neurosci. 2020;12:588872. https://doi.org/10.3389/fnagi.2020.588872.; World Health Organization (2020). Coronavirus Disease (COVID-19) Situation Report-190. Available at: https://who.int/docs/default-source/coronaviruse/situation-reports/20200928-weekly-epi-update.pdf?sfvrsn=9e354665_6.; Boutoleau-Bretonnière C., Pouclet-Courtemanche H., Gillet A., Bernard A., Deruet A.L., Gouraud I. et al. The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer’s Disease During the COVID-19 Crisis. J Alzheimers Dis. 2020;76(1):41–47. https://doi.org/10.3233/JAD-200604.; Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. https://doi.org/10.1001/jama.2020.2648.; Tsai S.T., Lu M.K., San S., Tsai C.H. The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review. Front Neurol. 2020;11:498. https://doi.org/10.3389/fneur.2020.00498.; Lim S., Bae J.H., Kwon H.S., Nauck M.A. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30. https://doi.org/10.1038/s41574-020-00435-4.; Cariou B., Hadjadj S., Wargny M., Pichelin M., Al-Salameh A., Allix I. et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63(8):1500–1515. https://doi.org/10.1007/s00125-020-05180-x.; Pitocco D., Viti L., Santoliquido A., Tartaglione L., Di Leo M., Bianchi A. et al. Diabetic neuropathy: a risk factor for severe COVID-19? Acta Diabetol. 2021;58(5):669–670. https://doi.org/10.1007/s00592-020-01658-7.; Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P. et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. https://doi.org/10.2337/dc10-1303.; Odriozola A., Ortega L., Martinez L., Odriozola S., Torrens A., Corroleu D. et al. Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection. Diabetes Res Clin Pract. 2021;172:108631. https://doi.org/10.1016/j.diabres.2020.108631.; Kioskli K., Scott W., Winkley K., Kylakos S., McCracken L.M. Psychosocial factors in painful diabetic neuropathy: a systematic review of treatment trials and survey studies. Pain Med. 2019;20:1756–1773. https://doi.org/10.1093/pm/pnz071.; Yang H., Sloan G., Ye Y., Wang S., Duan B., Tesfaye S., Gao L. New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front Endocrinol (Lausanne). 2020;10:929. https://doi.org/10.3389/fendo.2019.00929.; Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R. et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–962. https://doi.org/10.2337/diacare.28.4.956.; Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6(6):CD007543. https://doi.org/10.1002/14651858.CD007543.pub2.; Ang L., Jaiswal M., Martin C., Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. https://doi.org/10.1007/s11892-014-0528-7.; 1Cullen W., Gulati G., Kelly B.D. Mental health in the COVID-19 pandemic. QJM. 2020;113(5):311–312. https://doi.org/10.1093/qjmed/hcaa110.; Pérez-Cano H.J., Moreno-Murguía M.B., Morales-López O., Crow-Buchanan O., English J.A., Lozano-Alcázar J., Somilleda-Ventura S.A. Anxiety, depression, and stress in response to the coronavirus disease-19 pandemic. Cir Cir. 2020;88(5):562–568. https://doi.org/10.24875/CIRU.20000561.; Smarr K.L., Keefer A.L. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res (Hoboken). 2011;63(11 Suppl.):S454–466. https://doi.org/10.1002/acr.20556.; Richter P., Werner J., Heerlein A., Kraus A., Sauer H. On the validity of the Beck Depression Inventory. A review. Psychopathology. 1998;31(3):160–168. https://doi.org/10.1159/000066239.; Beck S.B. Еyelid conditioning as a function of cs intensity, ucs intensity, and manifest anxiety scale score. J Exp Psychol. 1963;66:429–438. https://doi.org/10.1037/h0042820.; Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. https://doi.org/10.1136/jnnp.23.1.56.; Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Lond). 2015;65(7):601. https://doi.org/10.1093/occmed/kqv054.; Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10:393–400. https://doi.org/10.1111/j.1526-4637.2008.00555.x.; Centre for Clinical Practice at NICE (UK). Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-specialist Settings. London: National Institute for Health and Care Excellence, (UK); 2013. Available at: https://pubmed.ncbi.nlm.nih.gov/25577930.; Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491–496. https://doi.org/10.1007/s40263-014-0164-4.; Tesfaye S., Vileikyte L., Rayman G., Sindrup S.H., Perkins B.A., Baconja M. et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629–638. https://doi.org/10.1002/dmrr.1225.; Lunn M.P., Hughes R.A., Wiffen P.J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014:Cd007115. https://doi.org/10.1002/14651858.CD007115.pub3.; Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114–121. https://doi.org/10.1111/j.1464-5491.2004.01109.x.; Строков И.А., Фокина А.С., Строков К.И., Дроконова О.О. Современные принципы диагностики и лечения диабетической полинейропатии. Медицинский совет. 2014;(5):38–43. https://doi.org/10.21518/2079-701X-2014-5-38-43.; Cure E., Cumhur Cure M. Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection. Med Hypotheses. 2020;143:110185. https://doi.org/10.1016/j.mehy.2020.110185.; Zhong M., Sun A., Xiao T., Yao G., Sang L., Zheng X. et al. A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19). medRxiv. 2020. https://doi.org/10.1101/2020.04.15.20066266.; Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., Gries F.A. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425–1433. https://doi.org/10.1007/BF00400603.; Ziegler D., Reljanovic M., Mehnert H., Gries F.A. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107(7):421–430. https://doi.org/10.1055/s-0029-1212132.; Ametov A.S., Barinov A., Dyck P.J., Hermann R., Kozlova N., Litchy W.J. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770–776. https://doi.org/10.2337/diacare.26.3.770.; Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q. et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9(3):294–299. https://doi.org/10.1038/nm834.; Ang C.D., Alviar M.J., Dans A.L., Bautista-Velez G.G., Villaruz-Sulit M.V., Tan J.J. et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008;(3):CD004573. https://doi.org/10.1002/14651858.CD004573.pub3.; Луцкий И.С., Лютикова Л.В., Луцкий Е.И. Витамины группы В в неврологической практике. Международный неврологический журнал. 2008;(5):89–93. Режим доступа: https://www.mif-ua.com/archive/article/7441.; Bâ A. Metabolic and structural role of thiamine in nervous tissues. Cell Mol Neurobiol. 2008;28(7):923–931. https://doi.org/10.1007/s10571-008-9297-7.; Haupt E., Ledermann H., Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther. 2005;43(2):71–77. https://doi.org/10.5414/cpp43071.; Stracke H., Gaus W., Achenbach U., Federlin K., Bretzel R.G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600–605. https://doi.org/10.1055/s-2008-1065351.; Mooney S., Leuendorf J.E., Hendrickson C., Hellmann H. Vitamin B6: a long known compound of surprising complexity. Molecules. 2009;14(1):329–351. https://doi.org/10.3390/molecules14010329.; Markle H.V. Cobalamin. Crit Rev Clin Lab Sci. 1996;33(4):247–356. https://doi.org/10.3109/10408369609081009.; Павлов Ч.С., Дамулин И.В., Шульпекова Ю.О., Андреев Е.А. Неврологические расстройства при дефиците витамина В12. Терарапевтический архив. 2019;91(4):122–129. Режим доступа: https://cyberleninka.ru/article/n/nevrologicheskie-rasstroystva-pridefitsite-vitamina-v12.; Jayabalan B., Low L.L. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J. 2016;57(2):55–59. https://doi.org/10.11622/smedj.2016027.; Верткин А.Л., Городецкий В.В. В чем преимущество бенфотиаминсодержащих препаратов Мильгамма и Бенфогамма в лечении диабетической полинейропатии. Фарматека. 2006;(11):83–89. Режим доступа: https://pharmateca.ru/ru/archive/article/6589.; Маркина О.А. Значение лекарственной формы и пути введения витаминов группы В для обеспечения эффективного лечения диабетической полиневропатии. Клиническая фармакология и терапия. 2003;(2):6–9. Режим доступа: https://medi.ru/info/11187.; Парфенов В.А., Головачева В.А., Фадеев В.В., Воловик А.Ю., Головачева А.А. Оптимизация ведения пациентов с диабетической полиневропатией с помощью междисциплинарного подхода. Медицинский совет. 2017;(1S):71–79. https://doi.org/10.21518/2079-701X-2017-0-71-79.; Манушарова Р.А., Черкезов Д.И. Применение Нейромультивита при диабетической периферической полинейропатии. Медицинский совет. 2011;(1-2):68–71. Режим доступа: https://cyberleninka.ru/article/n/primenenie-neyromultivita-pri-diabeticheskoy-perifericheskoypolineyropatii.; Токмакова А.Ю., Анциферов М.Б. Возможности использования нейромультивита в комплексной терапии полинейропатии у больных сахарным диабетом. Сахарный диабет. 2001;4(2):33–35. https://doi.org/10.14341/2072-0351-5660.; Al Sulaiman K., Aljuhani O., Al Dossari M., Alshahrani A., Alharbi A., Algarni R. et al. Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study. Crit Care. 2021;25(1):223. https://doi.org/10.1186/s13054-021-03648-9.; Branco de Oliveira M.V., Irikura S., Lourenço F.H. B., Shinsato M., Irikura T.C. D. B., Irikura R.B. et al. Encephalopathy responsive to thiamine in severe COVID-19 patients. Brain Behav Immun Health. 2021;14:100252. https://doi.org/10.1016/j.bbih.2021.100252.; Shakoor H., Feehan J., Mikkelsen K., Al Dhaheri A.S., Ali H.I., Platat C. et al. Be well: A potential role for vitamin B in COVID-19. Maturitas. 2021;144:108–111. https://doi.org/10.1016/j.maturitas.2020.08.007.; Kumrungsee T., Zhang P., Chartkul M., Yanaka N., Kato N. Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications. Front Nutr. 2020;7:562051. https://doi.org/10.3389/fnut.2020.562051.; Lopes M.J. S. Can vitamin B12 be an adjuvant to COVID-19 treatment? GSC Biological and Pharmaceutical Sciences. 2020;11(3):1–5. Available at: https://gsconlinepress.com/journals/gscbps/content/can-vitamin-b12-beadjuvant-covid-19-treatment.; Менделевич Е.Г. Дефицит витаминов группы В: аспекты диагностики и терапии. РМЖ. 2016;24(7):442–444. Режим доступа: https://rmj.ru/articles/nevrologiya/Deficit_vitaminov_gruppy_V_aspekty_diagnostikii_terapii.; Бирюкова Е.В., Ганненкова Е.С., Соловьева И.В. Диабетическая полинейропатия: чего мы достигли в понимании проблемы? РМЖ. 2020;28(1):14–19. Режим доступа: https://rmj.ru/articles/endokrinologiya/Diabeticheskaya_polineyropatiya_chego_my_dostigli_v_ponimanii_problemy

  5. 5
  6. 6
    Academic Journal

    Πηγή: Meditsinskiy sovet = Medical Council; № 21 (2019); 94-102 ; Медицинский Совет; № 21 (2019); 94-102 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-21

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/5480/4999; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.) Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». 9-й выпуск. Москва; 2019;22(S1). Режим доступа: http://webmed.irkutsk.ru/doc/pdf/algosd.pdf.; Azmi Sh., Petropoulos I.N., Ferdousi M., Ponirakis G., Alam U., Malik R.A. An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy [version 1; peer review: 3 approved]. F1000Res. 2019;8(F1000 Faculty Rev):186. doi:10.12688/f1000research.17118.1.; Котов С.В., Калинин А.П., Рудакова И.Г. Диабетическая нейропатия. 2-е изд., пере- раб. и доп. М.: ООО «МИА»; 2011.301 с.; Vučković-Rebrina S., Barada A., Smirčić- DuvnjakL. Diabetic Autonomic Neuropathy. Diabetologia Croatica. 2013;42(3):73–79. Available at: http://www.idb.hr/diabetologia/13no3-2.pdf.; Haq T., Ahmed T., Latif Z.A., Sayeed M.A., Ashrafuzzaman S.M. Cardiac autonomic neuropathy in patients with type 2 diabetes mellitus having peripheral neuropathy: A crosssectional study. Diabetes Metab Syndr. 2019;13(2):1523–1528. doi:10.1016/j.dsx.2019.03.015.; Dewanjee S., Das S., Das A.K., Bhattacharjee N., Dihingia A., Dua T.K., et al. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. Eur J Pharmacol. 2018;833:472–523. doi:10.1016/j.ejphar.2018.06.034.; Spallone V. Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet. Diabetes Metab J. 2019;43(1):3–30. doi:10.4093/dmj.2018.0259.; Grewal A.S., Bhardwaj S., Pandita D., Lather V., Sekhon B.S. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases. Mini Rev. Med Chem. 2016;16(2):120–162. doi:10.2174/1389557515666150909143737.; Bonete G., Dias B.A.L., Leandro D.A.M., Fernande A.N., Pereira C.H., Ribeiro C.T., at al. Impaired Heart Rate Variability, Valsalva and 30:15 Ratio Indexes Are Associated With Reduced Submaximal Exercise Capacity in Subjects With Diabetes Mellitus. Diabetes Res Clin Pract. 2019;155:107813. doi:10.1016/j.diabres.2019.107813.; Serhiyenko V.A., Serhiyenko A.A. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 2018;9(1):1–24. doi:10.4239/wjd.v9.i1.1.; Fisher V.L., Tahrani A.A. Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017;10:419–434. doi:10.2147/DMSO.S129797.; Hillis Gr.S., Hata J., Woodward M., Perkovic V., Arima H., Chow C.K., et al. Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. J Am Heart Assoc. 2012;1(5):e002832. doi:10.1161/JAHA.112.002832.; Vinik A., Erbas T., Casellini C.M. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4(1):4–18. doi:10.1111/jdi.12042.; Gibbons C.H., Schmidt P., Biaggioni I., Frazier- Mills C., Freeman R., Isaacson S., et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567–1582. doi:10.1007/s00415-016-8375-x.; Bissinger A. Cardiac Autonomic Neuropathy: Why Should Cardiologists Care about That? J Diabetes Res. 2017;2017:5374176. doi:10.1155/2017/5374176.; Janovsky C.C., Rolim L.C., de Sa J.R., Poyares D., Tufik S., Silva A.B., Dib S.A. Cardiovascular autonomic neuropathy contributes to sleep apnea in young and lean type 1 diabetes mellitus patients. Front Endocrinol (Lausanne). 2014;5:119. doi:10.3389/fendo.2014.00119.; Agashe S., Petak S. Cardiac Autonomic Neuropathy in Diabetes Mellitus. Methodist Debakey Cardiovasc J. 2018;14(4):251–256. doi:10.14797/mdcj-14-4-251.; Валеева Ф.В., Шайдуллина М.Р. Диагностика диабетической автономной кардиальной нейропатии у больных сахарным диабетом 1 типа. Сахарный диабет. 2009;(4):56–60. Режим доступа: https://elibrary.ru/item.asp?id=13333729.; Gulichsen El., Fleischer J., Ejskjaer N., Eldrup Eb., Tarnow L. Screening for Diabetic Cardiac Autonomic Neuropathy Using a New Handheld Device. J Diabetes Sci Technol. 2012;6(4):965–972. doi:10.1177/193229681200600430.; Баринов А.Н. Вегетативная невропатия при сахарном диабете и метаболическом синдроме: клинические проявления, диагностика и лечение. Эффективная фармакотерапия. 2017;(2):40–52. Режим доступа: https://umedp.ru/articles/vegetativnaya_nevropatiya_pri_sakharnom_diabete_i_metabolicheskom_sindrome_klinicheskie_proyavleniya.html?sphrase_id=40778.; Gandhi R.A., Marques J.L.B., Selvarajah D., Emery C.J., Tesfaye S. Painful Diabetic Neuropathy Is Associated With Greater Autonomic Dysfunction Than Painless Diabetic Neuropathy. Diabetes Care. 2010;33(7):1585–1590. doi:10.2337/dc09-2314.; Сосина В.Б., Захаров В.В., Строков И.А., Вахнина Н.В. Когнитивные нарушения при сахарном диабете. Неврология, нейропсихиатрия, психосоматика. 2017;9(1):90–95. Режим доступа: https://nnp.ima-press.net/nnp/article/view/704?locale=ru_RU.; Kodl C.T., Seaquist E.R. Cognitive Dysfunction and Diabetes Mellitus. Endocr Rev. 2008;29(4):494–511. doi:10.1210/er.2007-0034.; Pop-Busui R., Boulton A.J., Feldman E.L., Bril V., Freeman R., Ziegler D., et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi:10.2337/dc16-2042.; Pop-Busui R., Evans G.W., Gerstein H.C., Fonseca V., Fleg J.L., Hoogwerf B.J., et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33(7):1578–1584. doi:10.2337/dc10-0125.; Esposito K., Giugliano D. Mediterranean diet and type 2 diabetes, Diabetes Metab Res Rev. 2014;30(S1):34–40. doi:10.1002/dmrr.2516.; Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., Gries F.A. Treatment of symptomatic diabetic peripheral neuropathy with the antioxydant alpha-lypoic acid. (ALADIN study group). Diabetologica. 1995;38:1425–1433. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8786016.; Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med. 2004;21:114–121. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14984445.; Аметов А.С. Рекомендации по лечению диабетической невропатии в России. РМЖ. 2010;14:869–878. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Rekomendacii_po_lecheniyu__diabeticheskoy_nevropatii_v_Rossii/; Mijnhout G.S., Kollen B.J., Alkhalaf A., Kleefstra N., Bilo H.J. Alpha lipoic Acid for symptomaticperipheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279. doi:10.1155/2012/456279.; Ziegler D., Schatz H., Conrad F., Gries F.A., Ulrich H., Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20(3):369–373. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9051389.; Akbari M., Ostadmohammadi V., Tabrizi R., Mobini M., Lankarani K.B., Moosazadeh M., et al. The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab. 2018;15:39. doi:10.1186/s12986-018-0274-y.; Строков И.А., Ахмеджанова Л.Т., Фокина А.С., Баринов А.Н. Патогенетическая терапия диа- бетической полиневропатии альфа-липоевой кислотой с точки зрения доказательной медицины. Эффективная фармакотерапия. 2019;(4):32–40. Режим доступа: http://umedp.ru/upload/iblock/022/effektivnaya_farmakoterapiya_nevrologiya_i_psikhiatriya_1_2019_VAK.pdf.; Jun J.E., Lee S.E., Choi M.S., Park S.W., Hwang Y.C., Kim J.H. Clinical factors associated with the recovery of cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2019;18:29. doi:10.1186/s12933-019-0830-4.; Spallone V., Bellavere F., Scionti L., Maule S., Quadri R., Bax G., et al. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovas Dis. 2011;21(1):69–78. doi:10.1016/j.numecd.2010.07.005.

  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
    Academic Journal
  12. 12
  13. 13
  14. 14
    Academic Journal

    Πηγή: Neuromuscular Diseases; № 4 (2012); 59-65 ; Нервно-мышечные болезни; № 4 (2012); 59-65 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2012-0-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/100/96; Куренков А.Л., Никитин С.С., Бурсагова Б.И., Кузенкова Л.М. Особенности хронической воспалительной демиелинизирующей полинейропатии у детей. Нервно-мышечные болезни 2012;2:40–51.; Аверочкин А.И., Мозолевский Ю.В., Штульман Д.Р. Заболевания периферической нервной системы. В кн.: Болезни нервной системы. Руководство. В 2 т. Под. ред. акад. РАМН Н.Н. Яхно. М.: Медицина, 2005. С.460–570; Quvrier R.A., McLeod J.G., Pollard J.D. Peripheral neuropathy in childhood. Mac Keith press. Sydney, Australia. 1999.; Van den Bergh P.Y.K., Hadden R.D.M., Bouche P. et al. Chronic inflammatory demyelinating polyradiculoneuropathy. In: N.E. Gilhus, M.P. Barnes, M. Brainin (eds.). European Handbook of Neurological Management. Oxford: Blackwell Publishing Ltd, 2011. P. 333–342.; Николаев С.Г. Атлас по электромиографии. Иваново: ИПК «ПресСто», 2010.; Гехт Б.М., Касаткина Л.Ф., Самойлов М.И., Санадзе А.Г. Электромиография в диагностике нервно-; мышечных заболеваний. Таганрог, 1997.; Левин О.С. Полинейропатии. М.: МИА, 2005.; Freeman R. Not all neuropathy in diabetes is of diabetic etiology: differentialdiagnosis of diabetic neuropathy. Curr Diab Rep 2009;9(6):423–31.; Azhary H., Farooq M.U., Bhanushali M. et al. Peripheral neuropathy: differential diagnosis and management. Am Fam Physician 2010;1;81(7):887–92.; Jann S., Bramerio M.A., Facchetti D., Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry 2009;80(1):70–3.; Ayyar D.R., Sharma K.R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus. Curr Diab Rep 2004;4(6):409–12.; Jann S., Bramerio M.A., Beretta S. et al. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 2003;61(11): 1607–10.; Lozeron P., Nahum L., Lacroix C. et al. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol 2002;249(5):569–75.; Dyck P.J., Norell J.E., Dyck P.J. Non-diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety. Brain 2001;124(Pt 6):1197–207.; Dyck P.J., Windebank A.J. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002;25(4):477–91.; Pascoe M.K., Low P.A., Windebank A.J, Litchy W.J. Subacute diabetic proximal neuropathy. Mayo Clin Proc 1997;72(12):1123–32.; Amato A.A., Barohn R.J. Diabetic Lumbosacral Polyradiculoneuropathies. Curr Treat Options Neurol 2001;3(2):139–46.; Rotta F.T., Sussman A.T., Bradley W.G. et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173(2):129–39.; Krendel D.A., Costigan D.A., Hopkins L.C. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995;52(11):1053–61.; https://nmb.abvpress.ru/jour/article/view/100

    Διαθεσιμότητα: https://nmb.abvpress.ru/jour/article/view/100

  15. 15
    Academic Journal

    Πηγή: Neuromuscular Diseases; № 1 (2012); 25-31 ; Нервно-мышечные болезни; № 1 (2012); 25-31 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2012-0-1

    Περιγραφή αρχείου: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/71/67; Wild S., Roglic G., Green A. et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047−53.; Котов С.В., Калинин А.П., Рудакова И.Г. Диабетическая нейропатия. М.: МИА, 2011. 438 с.; Consensus statement. Report and recommendation of the San Antonio conference on diabetic neuropathy. Diabetes 1988;11:592−7.; Зотова Е.В., Савостьянов К.В., Чистяков Д.А. и др. Поиск ассоциации полиморфных маркеров генов, кодирующих ферменты антиоксидантной защиты с диабетической полинейропатией у больных сахарным диабетом типа 1. Мол биол 2004;2:244−9.; Nikitin A.G., Chudakova D.A., Strokov I.A. et al. Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose) polymerase-1 gene are associa ed with diabetic polyneuropathy in Russian type 1 diabetic patients. Diabetes Res Clin Pract 2008;79 (3):446−52.; Dyck P.J.,Davis J.L., Litchy W.J. et al. Longitudinal assessment of diaberic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229−39.; Строков И.А., Новосадова М.В., Баринов А.Н. и др. Клинические методы оценки тяжести диабетической полиневропатии. Неврол журн 2000;5:14−9.; Ziegler D., Hanefeld M., Ruhnau K.J. et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicenter randomized controlled trial (ALADIN Study). Diabetologia 1995;38:1425−33.; Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practices. 2-nd Ed, Philadelphia, F.A. Davis, 1989.; Dyck P.J.B., Dyck P.J. Diabetic polyneuropathy. In: Diabetic polyneuropathy. P.J. Dyck, P.K. Thomas ed. 2nd eds., Philadelphia, Pa: W.B. Saunders 1999:255−78.; Boulton A.J.M., Vinik A.I., Arezzo J.C. et al. Diabetic neuropathy. A statement by the American Diabetes Association. Diabetes Care 2005; 28:956−62.; Knuiman M.W., Welborn T.A., McCann V.J. et al. Prevalence of diabetic complications in relation to risk factors. Diabetes 1986;35:1332−9.; Dyck P.J., Kratz K.M., Karnes J.L. et al. The prevalence by stages severity of various types of diabetic neuropathy, retinopathy, and nephropathy in population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817−24.; Kästenbauer T., Irsigler P., Sauseng S. et al. The prevalence of symptoms of sensorimotor and autonomic neuropathy in Type 1 and Type 2 diabetic subjects. J Diab Compl 2004;18:27−31.; Gabezas-Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groupe. Neuropathy Spanish Study Groupe of the Spanish Diabetes Society (SDS). Diabetologia 1998;41:1263−9.; Young M.J., Boulton A.J., MacLeod A.F. et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150−4.; Nelson D., Mah J.K., Adams C. et al. Comparison of conventional and non-invasive techniques for the early identification of diabetic neuropathy in children and alolescents with type 1 diabetes. Pediatr Diabetes 2006; 7:305−10.; Nordwall M., Hyllienmark L., Ludvigsson J. Early diabetic complications in a population of young patients with type 1 diabetes mellitus despite intensive treatment. J Pediatr Endocrinol Metab 2006;19:45−54.; Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005;54:1615−25.; Albers J.W., Herman W.H., Pop-Busui R. et al. Effect of prior intensive insulin treatment during the DCCT on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010;33:1090−6.; DCCT Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977−86.; Herman W.H., Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005; 28:1480−1.; Thomas P.K. Classification of diabetic neuropathy. Textbook of diabetic neuropathy. 2003:175−7.; El-Osta A., Brasacchio D., Yao D. et al. Transient high glucose causes persistent epigenetic changes and altered gene expression. J Exp Med 2008;205:2409−17.; Shaw J.E., Zimmer P.Z., Greis F.A., Ziegler D. Epidemiology of diabetic neuropathy. In: Textbook of Diabetic Neuropathy. New York: Thieme, 2002, p. 64–82.; Happich M., Breitscheidel L., Meisinger C. et al. Cross-sectional analysis of adult diabetes type 1 and type 2 patients with diabetic microvascular complications from a German retrospective observational study. Curr Med Res Opin 2007;23:1367−74.; De Block C.E.M., De Leeuv I.H., Van Gaal L.F. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005; 28:1649−55.; Forrest K.Y., Maser R.E., Pambianco G. et al. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997;46:665−70.; https://nmb.abvpress.ru/jour/article/view/71

  16. 16
  17. 17
  18. 18
  19. 19
  20. 20